quinazolines has been researched along with neurotensin in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bennett, M; Buamah, PK; James, OF; Lendrum, R; McArdle, P | 1 |
| Cayre, A; De Wever, O; Doan, VK; Dupouy, S; Forgez, P; Gompel, A; Kouchkar, A; Liu, J; Llorca, FP; Mourra, N; Wu, Z | 1 |
| Alifano, M; Damotte, D; Dupouy, S; Fléjou, JF; Forgez, P; Lupo, AM; Mourra, N; Régnard, JF; Takahashi, T; Trédaniel, J; Wu, Z; Younes, M | 1 |
| Jensen, RT; Moody, TW; Nakamura, T; Nuche-Berenguer, B | 1 |
1 review(s) available for quinazolines and neurotensin
| Article | Year |
|---|---|
EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.
Topics: Antineoplastic Agents; Bombesin; Cell Proliferation; Cholecystokinin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neurotensin; Protein Kinase Inhibitors; Quinazolines; Receptors, G-Protein-Coupled | 2016 |
3 other study(ies) available for quinazolines and neurotensin
| Article | Year |
|---|---|
A pleomorphic hepatocellular carcinoma with biochemical features of fibrolamellar hepatocellular carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Combined Modality Therapy; Doxorubicin; Etoposide; Female; Folic Acid; Humans; Liver Neoplasms; Neurotensin; Quinazolines; Vitamin B 12 | 1986 |
Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Humans; Lapatinib; MCF-7 Cells; Metformin; Middle Aged; Neoplasm Invasiveness; Neurotensin; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Transfection; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2014 |
Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Animals; Autocrine Communication; Cell Line, Tumor; Cell Proliferation; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Female; Heparin-binding EGF-like Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Matrix Metalloproteinase 1; Mice, Nude; Middle Aged; Neoplasm Staging; Neuregulin-1; Neurotensin; Paracrine Communication; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptors, Neurotensin; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |